MIST
Milestone Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.20
−0.83%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -42.9%
- EBIT
- -42.6%
- EPS
- +18.8%
- Free cash flow
- -51.4%
- Operating cash flow
- -51.5%
Forward estimates
Based on analyst estimates
- Revenue
- +346.3%
- EBITDA
- -52.8%
- EPS
- -30.9%
Three-year CAGR
- Revenue
- -32.4%
- EBITDA
- -57.1%
- EBIT
- -48.4%
- Net income
- -51.9%
- EPS
- -11.9%
- Free cash flow
- -70.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026